-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, V3mkZ/KxQ5XS7CeN6n9lmikv8/sUd9cGfKOM/VEzxKb+QSbxFmzLt9fcB7jXJUqE aPXd0g2Wv3ztNgGRNRB3Yw== 0001169232-05-002223.txt : 20050421 0001169232-05-002223.hdr.sgml : 20050421 20050421105708 ACCESSION NUMBER: 0001169232-05-002223 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050415 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20050421 DATE AS OF CHANGE: 20050421 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CARACO PHARMACEUTICAL LABORATORIES LTD CENTRAL INDEX KEY: 0000887708 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 382505723 STATE OF INCORPORATION: MI FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31773 FILM NUMBER: 05763576 BUSINESS ADDRESS: STREET 1: 1150 ELIJAH MCCOY DR CITY: DETROIT STATE: MI ZIP: 48202 BUSINESS PHONE: 3138718400 MAIL ADDRESS: STREET 1: 1150 ELIJAH MCCOY DRIVE CITY: DETROIT STATE: MI ZIP: 48202 8-K 1 d63455_8-k.htm FORM 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

April 15, 2005

(Date of report)

 

CARACO PHARMACEUTICAL LABORATORIES, LTD.

(Exact name of registrant as specified in its charter)

 

 

Michigan

 

0-24676

 

38-2505723

(State or other jurisdiction of incorporation)

 

(Commission file number)

 

(I.R.S. employer identification no.)

 

 

1150 Elijah McCoy Drive, Detroit, Michigan 48202

(Address of principal executive offices)

 

(313) 871-8400

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12)

 

o 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 


 

 

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

 

(a)           Not Applicable;

 

(b)           Effective May 2, 2005, when Daniel H. Movens will become the Company’s CEO, (see subparagraph (c) below), the Company’s current interim CEO, Jitendra N. Doshi, will continue as its Chief Operating Officer and Chief Financial Officer.

 

(c)           On April 15, 2005, the Compensation Committee and the Board of Directors approved the appointment of Daniel H. Movens as the Company’s new CEO effective May 2, 2005. In addition, the Board of Directors also appointed Mr. Movens as a director of the Company effective May 2, 2005. Mr. Movens, together with Messrs. Sailesh T. Desai and Georges Ugeux were also nominated to serve as directors, subject to shareholder approval at the Company’s annual meeting of shareholders scheduled for June 20, 2005, until 2008 and the qualification and election of their successors.

 

Mr. Movens joined Anda, Inc., a wholly-owned subsidiary of Andrx Corporation, in 1995 and was named President of Anda, Inc, in February, 2004, after holding a number of positions of increasing responsibility, including Executive Vice President of Operations. For fifteen (15) years before joining Anda, Inc., Mr. Movens worked in the retail pharmacy industry, working for independent pharmacies and pharmacy chains.. During 2004, Caraco sold $5.4 million of products to Anda, Inc.

 

The final terms of an employment agreement between the Company and Mr. Movens, which it is anticipated will be executed on or before the Effective Date, will be disclosed in the next applicable report of the Company filed with the SEC.

 

 

 


 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

CARACO PHARMACEUTICAL LABORATORIES, LTD.

 

 

Date: April 21, 2005

By:      /s/ Jitendra N. Doshi
         ———————————
                 Jitendra N. Doshi

                 Chief Executive Officer

 

 

2



 -----END PRIVACY-ENHANCED MESSAGE-----